Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT02643147

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02643147
Other papers using this trial's data
  • Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction Revista espanola de cardiologia (English ed.), 2021-07 DOI, PubMed 32624444

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02643147. Randomized; single masking; primary purpose treatment. Start 2015-01 (actual); primary completion 2017-01-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)
Acronym
IMPROVE-HF
Condition
Heart Failure
Intervention (Drug)
CA125 guided strategy
Intervention (Drug)
CA125 guided strategy
Intervention (Drug)
Conventional Strategy
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia (class: other)

Record details

Record id
cardio:ct-nct02643147
Content hash
3221b391af372c6cf46bcc28027a9550fd05cba3f2ca9d2f9141c1ca17959c05